treatment of seizure

Comparison of efficacy of add on oral serratiopepitadase for reducing severity of headache during the acute phase of perilesional edema in calcifiedÂ neurocysticercosis: an open labeled randomized controlled trial - SPIHNC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/12/039005

Enrollment

102

Registered

2021-12-29

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G060- Intracranial abscess and granuloma

Interventions

Intervention1: Serratiopeptidase: oral serratiopeptidase 5 mg BD for 7 days with oral paracetamol 15 mg/kg as an d when required Control Intervention1: paracetamol alone: oral paracetamol 15 mg/kg as

Eligibility

Inclusion criteria

Inclusion criteria: Calcified NCC Perilesional edema on CT or MRI brain Headache for at least 48 hours, not attributable to any other etiology

Exclusion criteria

Exclusion criteria: Viable Neurocysticercosis Absence of perilesional oedema on neuroimaging Any coexisting primary or secondary headache etiology Previously documented allergy to serratiopeptidase

Design outcomes

Primary

Measure	Time frame
HIT score in both armsTimepoint: At baseline and at 1 week follow up	—

Secondary

Measure	Time frame
Reduction in HIT score in both arms on day 14 on follow up as compared to baselineTimepoint: Reduction in HIT score in both arms on day 14 on follow up as compared to baseline	—

Countries

India

Contacts

Public ContactPrateek Kumar Panda

Department of Pediatrics, AIIMS, Rishikesh

drprateekpanda@gmail.com09650149735

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026